 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
      
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
議程
語言選擇
  
 
|
演講者John L. Allinson, FIBMS, Director, Veeda Clinical Research Ltd. Miriam Bayes, Ph.D., Head Scientific & Content Development, Thomson Scientific Jens Beator, Ph.D., Director, Protein Biochips, Protagen AG Christine Betard, Ph.D., Senior Director, Global Strategic Drug Development Unit, Quntiles Michael E. Burczynski, Ph.D., Associate Director, Biomarker Laboratory, Clinical Translational Medicine, Wyeth Research Raffaella Castoldi, M.S., Head of Analytical Biology, DMPK, Accelera/Nerviano Medical Sciences Daniel Chelsky, Ph.D., Chief Scientific Officer, Caprion Proteomics Tao Chen, Ph.D., Research Toxicologist, Division of Genetic and Reproductive Toxicology, FDA/NCTR Viswanath Devanarayan, Ph.D., Director, Statistics, Biomarker Research, Abbott Laboratories Enrico Domenici, Ph.D., Director, Molecular Psychiatry, GSK Medicines Research Centre Nicholas C. Dracopoli, Ph.D., Vice President, Biomarkers, Centocor R&D, Johnson & Johnson Darius Dziuda, Ph.D., Assistant Professor, Mathematical Sciences, Central Connecticut State University Dave Englert, Ph.D., Vice President, Technology Development, Xceed Molecular Andreas Freidig, Ph.D., Senior Scientist, BU Biosciences, TNO, Quality of Life Herbert A. Fritsche, Ph.D., Professor and Chief of Clinical Chemistry, The University of Texas M. D. Anderson Cancer Center Philip M. Hemken, Ph.D., Principle Scientist, Cancer Research Diagnostics, Abbott Laboratories Yiwu He, Ph.D., MBA, Senior Program Officer, Global Health, The Bill &Melinda Gates Foundation Debra A. Hope, Ph.D., MBA, Director, Business Development, Theranostics Health Joanna Hunter, Ph.D., Director, Protein Analysis, Caprion Proteomics Inc. Gordon F. Kapke, Ph.D., Senior Director, Biomarker Services, Covance Central Laboratory Services Clare Kingsley, Ph.D., Client Manager, Biomarkers, HFL Ltd. Geert Kolvenbag, M.D., Ph.D., Executive Director, Development, Emerging Oncology and Infection Brands, AstraZeneca Rajesh Krishnan, Ph.D., Director, Business Development and Strategic Alliances, Pathway Diagnostics Mark R. Lackner, Ph.D., Scientist, Development Oncology Diagnostics, Genentech Inc. Ole Lagatie, Ph.D., Scientific Advisor, Bioanalysis, Eurofins Medinet Eric Lai, Ph.D., Vice President, Pharmacogenetics Experimental Project Coordination and Analysis, GlaxoSmithKline Michael N. Liebman, Ph.D., Senior Institute Fellow, Windber Research Institute Cathy Lofton-Day, Ph.D., Vice President, Molecular Biology, Diagnostics, Epigenomics, Inc. Peter Maimonis, Ph.D., Vice President, Biological Research, Decision Biomarkers Inc. Elizabeth Mansfield, Ph.D., Senior Policy Analyst, Office of Diagnostic Device Evaluation and Safety (OIVD), Center for Devices and Radiologic Health, US Food and Drug Administration Shawnmarie Mayrand-Chung, Ph.D., J.D., NIH Program Director, The Biomarkers Consortium; Public-Private Partnership Program, Office of Science Policy, Office of the Director, National Institutes of Health S𡜐en M㘾ler, Ph.D., Chief Scientific Officer, Vice President, R&D, Exiqon A/S Nagaraja Muniappa, Ph.D., DVM, Senior Investigator, Pathology, Safety Assessment, Merck Research Laboratories Art Okamoto, Ph.D., Senior Product Manager, Ingenuity Pathways Analysis, Ingenuity Systems Scott D. Patterson, Ph.D., Executive Director, Medical Sciences, Amgen Inc. Paul H. Pevsner, M.D., Research Associate Professor of Pharmacology, New York University School of Medicine J. Suso Platero, Ph.D., Associate Director, Clinical Biomarkers, Discovery Medicine and Clinical Pharmacology, Bristol-Myers Squibb Co. Steven J. Potts, Ph.D., MBA, Scientific Director, Biotechnology and Pharmaceutical, Aperio Technologies Uma Prabhakar, Ph.D., Senior Director, Biomarkers, Centocor Inc. Mitch Raponi, Ph.D., Principal Research Scientist, Biomarkers and Translational Research, Centocor Research & Development Paul Rhyne, Ph.D., Associate Director, Bioanalytical Sciences, Research and Development, Bristol-Myers Squibb Co. Michael Samoszuk, M.D., Chief Medical Officer, Roche Diagnostics Corp. Peter Schulz-Knappe, Ph.D., Chief Scientific Officer, Proteome Sciences plc Andreas Schuppert, Ph.D., Director, Applied Sciences, Bayer Technology Services GmbH Martin Shaw, Senior Scientific Officer, Biotrin International Adam J. Simon, Ph.D., Senior Research Fellow, Biomarkers, Integrative Systems Neuroscience, Merck Research Laboratories Keld Sorensen, Ph.D., Director, Research & Development, Luminex Bioscience Group Thomas F. Soriano, President and Chief Executive Officer, DOCRO, Inc. Philip Stegmaier, Research Scientist, Research & Development, BIOBASE GmbH Michael Stocum, Managing Director, Personalized Medicine Partners Anna E. Szafranska, Ph.D., Senior Scientist, Asuragen Inc. Stephen Tahir, Ph.D., Research Investigator, Cancer, Abbott Laboratories Patrick Terry, Co-founder, Director of Industry Relations, Genomic Health, Inc. David C. Thompson, Ph.D., Research Fellow, Drug Safety Research & Development, Pfizer Inc. Miro Venturi, Ph.D., Novartis Biologics Katerina Vlasakova, Research Associate, Systems Toxicology, Safety Assessment, Merck Research Laboratories John A. Wagner, M.D., Ph.D., Executive Director, Clinical Pharmacology, Merck Research Laboratories Elizabeth Gribble Walker, Ph.D., Assistant Director, Toxicology, Predictive Safety Testing Consortium, Critical Path Institute Yixin Wang, Ph.D., Executive Director, Research & Development, Veridex, LLC., a Johnson & Johnson Company Jeffrey F. Waring, Ph.D., Associate Research Fellow, Group Leader, Abbott Laboratories Thomas J. White, Ph.D., Chief Scientific Officer, Celera Mark Wilkinson, Ph.D., Assistant Professor, Medical Genetics and Bioinformatics, James Hogg iCAPTURE Centre Mark Wing, Ph.D., Director, Clinical and Translational Sciences Alan H.B. Wu, Ph.D., Professor, Department of Laboratory Medicine, Director, Clinical Chemistry, Toxicology and Pharmacogenomics Laboratories, University of California, San Francisco Yan J. Zhang, Ph.D., Senior Research Investigator, Clinical Biomarker Development, Bioanalytical Science, Bristol-Myers Squibb Co. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
